ALIGOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.59 USD | -1.67% |
|
+1.72% | -11.14% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,054 | 505.9 | 40.8 | 49.75 | 46.08 | - | - |
| Enterprise Value (EV) 1 | 1,054 | 505.9 | 40.8 | 49.75 | 46.08 | 46.08 | 46.08 |
| P/E ratio | -2.54 x | -3.69 x | -0.42 x | -0.49 x | -0.8 x | -0.94 x | -0.81 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 116 x | 2.93 x | 5.33 x | 46.4 x | - | - |
| EV / Revenue | - | 116 x | 2.93 x | 5.33 x | 46.4 x | - | - |
| EV / EBITDA | -10,772,944 x | -3,942,100 x | - | - | - | - | - |
| EV / FCF | -13,808,485 x | -4,340,084 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - |
| Price to Book | 4.6 x | 2.74 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 38,118 | 42,616 | 42,816 | 74,932 | 78,110 | - | - |
| Reference price 2 | 27.65 | 11.87 | 0.9529 | 0.6640 | 0.5900 | 0.5900 | 0.5900 |
| Announcement Date | 3/23/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 4.359 | 13.91 | 9.338 | 0.993 | - | - |
| EBITDA | - | -97.83 | -128.3 | - | - | - | - | - |
| EBIT 1 | - | -97.83 | -128.3 | -97.58 | -88.13 | -101.2 | -119.6 | -145.2 |
| Operating Margin | - | - | -2,943.82% | -701.66% | -943.75% | -10,194.56% | - | - |
| Earnings before Tax (EBT) 1 | - | -108.4 | -128.2 | -95.94 | -86.88 | -114 | -119.6 | -145.2 |
| Net income 1 | -52.38 | -108.5 | -128.3 | -96.05 | -87.68 | -115.4 | -110.8 | -128.2 |
| Net margin | - | - | -2,944.07% | -690.63% | -938.95% | -11,618.78% | - | - |
| EPS 2 | -2.780 | -10.87 | -3.220 | -2.250 | -1.360 | -0.7400 | -0.6300 | -0.7300 |
| Free Cash Flow | - | -76.33 | -116.6 | - | - | - | - | - |
| FCF margin | - | - | -2,673.87% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/20 | 3/23/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.367 | 2.571 | 3.693 | 4.106 | 3.537 | 2.723 | 6.886 | 3.239 | 2.009 | 0.986 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -37.95 | -35.56 | -20.39 | -18.95 | -22.68 | -23.92 | -19.14 | -19.07 | -26 | -22.05 | -25 | -26.25 | -27.93 | -28.49 | -29.06 |
| Operating Margin | -10,340.05% | -1,383% | -552.21% | -461.47% | -641.28% | -878.37% | -277.97% | -588.79% | -1,294.03% | -2,235.9% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -37.77 | -35.56 | -19.88 | -18.66 | -21.84 | -22.92 | -18.03 | -18.01 | -27.92 | -34.84 | -25 | -26.25 | -27.93 | -28.49 | -29.06 |
| Net income 1 | -37.71 | -35.56 | -19.92 | -18.62 | -21.89 | -22.96 | -18.79 | -18.04 | -27.89 | -34.86 | -24.8 | -26.78 | -28.92 | -28.49 | -29.06 |
| Net margin | -10,276.29% | -1,383.2% | -539.51% | -453.51% | -618.77% | -843% | -272.89% | -556.99% | -1,388.35% | -3,535.8% | - | - | - | - | - |
| EPS 2 | -0.8900 | -0.8400 | -0.4700 | -0.4400 | -0.5100 | -0.5300 | -0.4300 | -0.4100 | -0.2200 | -0.2200 | -0.1600 | -0.1700 | -0.1850 | -0.1800 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/4/22 | 8/4/22 | 11/2/22 | 3/9/23 | 5/4/23 | 8/3/23 | 11/2/23 | 3/12/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -76.3 | -117 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -140% | -63.4% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -52.7% | -51.3% | - | - | - | - | - |
| Assets 1 | - | 205.9 | 250.3 | - | - | - | - | - |
| Book Value Per Share | - | 6.010 | 4.330 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | 2.06 | 0.89 | - | - | - | - | - |
| Capex / Sales | - | - | 20.46% | - | - | - | - | - |
| Announcement Date | 8/26/20 | 3/23/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.59
USD
Average target price
4
USD
Spread / Average Target
+577.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.14% | 46.08M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ALGS Stock
- Financials Aligos Therapeutics, Inc.
